ALXN1850 for Hypophosphatasia

(MULBERRY Trial)

Not currently recruiting at 56 trial locations

Overseen By Alexion Pharmaceuticals, Inc. (Sponsor)

Age: < 18

Sex: Any

Trial Phase: Phase 3

Sponsor: Alexion Pharmaceuticals, Inc.

Disqualifiers: Cardiovascular, Respiratory, Hepatic, Renal, others

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 78

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment, ALXN1850 (Efzimfotase alfa), for children with hypophosphatasia (HPP), a condition affecting bone development and strength. Researchers aim to determine if ALXN1850 improves bone health compared to a placebo. The trial seeks children who have not received asfotase alfa and show signs of HPP on bone X-rays. Participants will receive ALXN1850 or a placebo through regular injections for 24 weeks, with the option to continue treatment for up to 132 weeks. Children with bone issues from HPP who haven't tried asfotase alfa may be suitable for this study. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to a potentially groundbreaking treatment for HPP.

Do I need to stop my current medications for the ALXN1850 trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that ALXN1850, a treatment in development for hypophosphatasia (HPP), underwent safety testing in earlier studies. These studies with adults found that ALXN1850 is generally well-tolerated, with most participants not experiencing serious side effects. The side effects that did occur were usually mild and temporary. This suggests that ALXN1850 is safe for humans, but further research is needed to confirm its safety in children. It's important to remember that this treatment remains under investigation, so new information may emerge as more participants join the trials. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for hypophosphatasia?

ALXN1850 is unique because it offers a potentially more convenient dosing schedule for hypophosphatasia, with injections every two weeks instead of more frequent administrations required by current treatments like enzyme replacement therapies. Unlike standard treatments that primarily focus on supplementing deficient enzymes, ALXN1850's bodyweight-dependent dosing could optimize effectiveness tailored to individual needs. Researchers are excited about the possibility of improved patient adherence and outcomes, making life easier for those managing this rare bone disorder.

What evidence suggests that ALXN1850 might be an effective treatment for hypophosphatasia?

Research has shown that ALXN1850, also known as efzimfotase alfa, might help treat hypophosphatasia (HPP). This treatment replaces a missing enzyme that aids the body in using phosphate and calcium to build strong bones. Early studies in adults demonstrated that ALXN1850 can lower certain markers indicating disease severity. This trial will evaluate ALXN1850 as an experimental treatment, while another group will receive a placebo. These findings suggest that ALXN1850 could improve bone health in people with HPP, offering hope for those affected by the condition. ^{1 4 6 7 8}

Are You a Good Fit for This Trial?

This trial is for children with Hypophosphatasia (HPP) who haven't been treated before. They must have a documented ALPL gene variant, high plasma PLP levels, be in early puberty or less, and show signs of HPP-related rickets on X-rays. Kids can't join if they've had recent fractures, allergies to the study drug ingredients, other bone diseases like hyperparathyroidism or hypoparathyroidism (unless due to HPP), or any major health issues that could affect the study.

Inclusion Criteria

I have HPP with rickets shown in X-rays and low ALP levels for my age and sex.

You have a specific gene variant or high levels of plasma PLP, or are in Tanner stage 2 or less.

Exclusion Criteria

I have been diagnosed with hyperparathyroidism.

I do not have any major health issues that could affect how my body handles medication.

I am not planning any surgery that could affect the study's results.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Randomized Evaluation Period

Participants receive either ALXN1850 or placebo every 2 weeks via subcutaneous injection

24 weeks

12 visits (in-person)

Open-label Extension (OLE) Period

Participants receive ALXN1850 every 2 weeks via subcutaneous injection

Up to 132 weeks

Up to 66 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• ALXN1850
• Placebo

Trial Overview

The trial tests ALXN1850 against a placebo to see how well it works on improving bone problems seen on X-rays in kids with HPP. It's designed to compare changes between those who get the real medicine and those who get a dummy pill without active ingredients.

How Is the Trial Designed?

Group I: ALXN1850 Experimental Treatment 2 Interventions

Starting at Day 1 of the Randomized Evaluation Period, the ALXN1850 group will receive bodyweight dependent doses of either 20mg, 35mg or 50mg of ALXN1850 once every 2 weeks (q2w) via SC injection, for 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.

Group II: Placebo Placebo Group 1 Intervention

Starting at Day 1 during the Randomized Evaluation Period, participants will receive placebo q2w for a total of 24 weeks. Participants will enter the OLE Period and continue q2w dosing with ALXN1850 for up to 132 weeks.

Who Is Running the Clinical Trial?

Alexion Pharmaceuticals, Inc.

Lead Sponsor

Trials

267

Recruited

141,000+

Dr. Alberto R. Martinez

Alexion Pharmaceuticals, Inc.

Chief Medical Officer since 2010

MD from University of Sao Paulo

Marc Dunoyer

Alexion Pharmaceuticals, Inc.

Chief Executive Officer since 2021

PhD in Molecular Biology

Alexion

Lead Sponsor

Trials

247

Recruited

38,600+

Marc Dunoyer

Alexion

Chief Executive Officer since 2021

PhD in Molecular Biology, University of Brussels

Christophe Hotermans

Alexion

Chief Medical Officer since 2021

MD, University of Leuven

Published Research Related to This Trial

In a 13-week study involving 27 adults with pediatric-onset hypophosphatasia, asfotase alfa, an enzyme replacement therapy, demonstrated increased exposure and consistent bioavailability across different body mass index categories, supporting its use at a recommended dose of 6 mg/kg/week.

The pharmacokinetics of asfotase alfa showed that its activity was dose-proportional and that steady state was achieved by approximately day 29, indicating effective dosing and potential for reliable treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. Pan, WJ., Pradhan, R., Pelto, R., et al.[2022]

Asfotase alfa, the only approved treatment for hypophosphatasia (HPP), can interfere with thyroid hormone measurements in certain immunoassays that use alkaline phosphatase (ALP) as a labeling enzyme, leading to falsely low levels of free triiodothyronine (FT3) and free thyroxine (FT4).

In a study of three HPP patients, normal thyroid function was confirmed despite low FT3 and FT4 readings from the AIA-2000 immunoassay, highlighting the importance for clinicians to choose appropriate testing methods to avoid misinterpretation of thyroid function in patients receiving asfotase alfa.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Altered Thyroid Function Tests Observed in Hypophosphatasia Patients Treated with Asfotase Alfa. Kato, H., Hidaka, N., Koga, M., et al.[2022]

Asfotase alfa, an enzyme replacement therapy for hypophosphatasia, showed significant long-term benefits in 6 adults over 61-68 months, but clinical deterioration occurred after treatment was discontinued for 15-48 months.

Upon restarting asfotase alfa, patients demonstrated improvement, highlighting the need for close monitoring and clinical practice guidelines for managing treatment interruptions in hypophosphatasia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Impact of discontinuing 5 years of enzyme replacement treatment in a cohort of 6 adults with hypophosphatasia: A case series. Rockman-Greenberg, C., Josse, R., Francis, M., et al.[2022]

Enzyme replacement therapy (ERT) with asfotase alfa has been shown to reduce the severity of oral manifestations in children with hypophosphatasia (HPP), based on a review of 22 studies.

Earlier initiation of ERT is recommended for better oral health outcomes, although some studies reported cases of further primary tooth loss, highlighting the need for more detailed research on oral health improvements.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The impact of enzyme replacement therapy on the oral health manifestations of hypophosphatasia among children: a scoping review. Smart, G., Jensen, ED., Poirier, BF., et al.[2023]

Asfotase alfa, the only approved treatment for pediatric-onset hypophosphatasia, can interfere with certain immunoassays that utilize alkaline phosphatase (ALP), potentially leading to false positive or negative results in blood tests.

While asfotase alfa was detected in most ALP assays, it did not affect tests using alternative detection systems, and its interference could be eliminated through sample extraction, highlighting the importance of testing assays for this interference in treated patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Interference of Asfotase Alfa in Immunoassays Employing Alkaline Phosphatase Technology. Piec, ID., Tompkins, B., Fraser, WD.[2021]

In a study involving 19 adults and adolescents with hypophosphatasia (HPP), treatment with asfotase alfa significantly increased levels of pyridoxal 5'-phosphate (PLP) after 6 months, indicating its efficacy in normalizing TNSALP substrate levels.

Patients treated with asfotase alfa showed improvements in functional abilities, such as increased walking distance over 5 years, and the treatment was generally well tolerated with mild to moderate side effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Kishnani, PS., Rockman-Greenberg, C., Rauch, F., et al.[2020]

Asfotase alfa (AA), a bone-targeted enzyme replacement therapy, has significantly improved survival rates in severely affected infants with hypophosphatasia (HPP) and enhanced the quality of life for children and adults with the condition.

The review highlights the development of AA, including its design and clinical trial outcomes, while also addressing its limitations and potential adverse effects, establishing its critical role in the management of HPP.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy. Bowden, SA., Foster, BL.[2023]

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/39135540/

phase 1, dose-escalation study in adults with ...

Our results showed that efzimfotase alfa has acceptable safety and pharmacokinetics and is effective for reducing biomarkers (measurable ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11425692/

Safety, pharmacokinetics, and pharmacodynamics of ...

Efzimfotase alfa (ALXN1850) is a second-generation TNSALP ERT in clinical development for the treatment of HPP (Patent US 2021/0169994 A1). Structurally related ...

3.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06079359

NCT06079359 | Phase 3 Study of ALXN1850 in Treatment- ...

The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have ...

4.

io.nihr.ac.uk

io.nihr.ac.uk/wp-content/uploads/2025/07/36874-Efzimfotase-Alfa-for-Hypophosphatasia-V1.0-JUL2025-NON-CONF.pdf

Health Technology Briefing July 2025

Efzimfotase alfa works by replacing the alkaline phosphatase that the body needs to free phosphate. This allows it to bind together with calcium to build ...

5.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06079281

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent ...

The primary objective of this study is to assess the efficacy of ALXN1850 versus placebo on functional outcomes in adolescent and adult participants with HPP ...

6.

academic.oup.com

academic.oup.com/jbmr/article/39/10/1412/7732140

Safety, pharmacokinetics, and pharmacodynamics of ...

Efzimfotase alfa (ALXN1850) is a second-generation TNSALP enzyme replacement therapy in development for HPP. This first-in-human open-label, ...

7.

clinicaltrials.gov

clinicaltrials.gov/study/NCT04980248

Study of ALXN1850 in Participants With Hypophosphatasia ...

This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850

8.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11920343/

Medical Management of Hypophosphatasia: Review ...

Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. ... hypophosphatasia: 7 year outcomes ...